SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Avalon Pharmaceuticals (AVRX) -- Ignore unavailable to you. Want to Upgrade?


To: Paul Chiu who wrote (6)1/26/2007 1:09:23 AM
From: mcbio  Read Replies (1) | Respond to of 9
 
Interested in this one based on tiny market cap and pipeline but have concerns that their lead drug was in-licensed from Vertex. If such a promising drug, why would Vertex license it away? Sure they will still get royalties but I'm sure if the drug were more promising Vertex would have held on to it or held on for a better licensee. Thoughts?